Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Sarepta Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of August 25, 2025

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, alleging securities fraud related to the company's gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy. The lawsuit claims that Sarepta made false statements about the safety and revenue outlook of ELEVIDYS, misleading investors about its potential for broader application approval and growth in prescriptions [1][4][5]. Group 1: Allegations and Impact - The complaint alleges that Sarepta misled investors by claiming that ELEVIDYS was a safe therapy without significant risks, while failing to disclose serious safety concerns and adverse events associated with the treatment [4][5]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and that adverse events would lead to halted recruitment and increased regulatory scrutiny [5]. - Following the announcement of a patient death related to ELEVIDYS on March 18, 2025, Sarepta's stock price dropped by $27.81 per share, or 27.44%, closing at $73.54 [6]. Group 2: Subsequent Developments - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a halt in recruitment for some clinical studies, which caused the stock price to fall by $4.18 per share, or 7.13%, to close at $54.43 [7]. - A second patient death was reported on June 15, 2025, resulting in a significant stock price drop of $15.24 per share, or 42.12%, closing at $20.91 [8]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks associated with ELEVIDYS, leading to a further decline in stock price by $1.52 per share, or 8.01%, closing at $17.46 [9].